Celadon Pharmaceuticals (LSE:CEL) EV-to-EBIT : -8.39 (As of May. 22, 2024)

View and export this data going back to 2022. Start your Free Trial

What is Celadon Pharmaceuticals EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Celadon Pharmaceuticals's Enterprise Value is €67.58 Mil. Celadon Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was €-8.06 Mil. Therefore, Celadon Pharmaceuticals's EV-to-EBIT for today is -8.39.

The historical rank and industry rank for Celadon Pharmaceuticals's EV-to-EBIT or its related term are showing as below:

LSE:CEL' s EV-to-EBIT Range Over the Past 10 Years
Min: -9.36 Med: -8.2 Max: -6.97
Current: -8.39

During the past 5 years, the highest EV-to-EBIT of Celadon Pharmaceuticals was -6.97. The lowest was -9.36. And the median was -8.20.

LSE:CEL's EV-to-EBIT is ranked worse than
100% of 676 companies
in the Drug Manufacturers industry
Industry Median: 17.145 vs LSE:CEL: -8.39

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Celadon Pharmaceuticals's Enterprise Value for the quarter that ended in Dec. 2023 was €77.88 Mil. Celadon Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was €-8.06 Mil. Celadon Pharmaceuticals's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -10.35%.

Celadon Pharmaceuticals EV-to-EBIT Historical Data

The historical data trend for Celadon Pharmaceuticals's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Celadon Pharmaceuticals EV-to-EBIT Chart

Celadon Pharmaceuticals Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

EV-to-EBIT

-1.85

-9.69

Celadon Pharmaceuticals Semi-Annual Data
	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
EV-to-EBIT	Get a 7-Day Free Trial			-	-	-1.85	-	-9.69

Competitive Comparison of Celadon Pharmaceuticals's EV-to-EBIT

For the Drug Manufacturers - Specialty & Generic subindustry, Celadon Pharmaceuticals's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Celadon Pharmaceuticals's EV-to-EBIT Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Celadon Pharmaceuticals's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Celadon Pharmaceuticals's EV-to-EBIT falls into.

Celadon Pharmaceuticals EV-to-EBIT Calculation

Celadon Pharmaceuticals's EV-to-EBIT for today is calculated as:

EV-to-EBIT	=	Enterprise Value (Today)	/	EBIT (TTM)
	=	67.577	/	-8.057
	=	-8.39

Celadon Pharmaceuticals's current Enterprise Value is €67.58 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Celadon Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was €-8.06 Mil.

Celadon Pharmaceuticals (LSE:CEL) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Celadon Pharmaceuticals's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Dec. 2023 )	=	EBIT	/	Enterprise Value (Q: Dec. 2023 )
	=	-8.057	/	77.881235
	=	-10.35 %

Celadon Pharmaceuticals's Enterprise Value for the quarter that ended in Dec. 2023 was €77.88 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Celadon Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was €-8.06 Mil.

Celadon Pharmaceuticals EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Celadon Pharmaceuticals's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Celadon Pharmaceuticals (LSE:CEL) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Celadon Pharmaceuticals PLC (LSE:CEL) » Definitions » EV-to-EBIT

Comparable Companies

Traded in Other Exchanges

N/A

Address

32-33 Cowcross Street, London, GBR, EC1M 6DF

Website

https://www.celadonpharma.co.uk

Celadon Pharmaceuticals PLC focuses on growing indoor hydroponic high-quality cannabis initially for use within the chronic pain market. It has two reportable segments Celadon is a Build of grow facilities, growing medical grade cannabis and research in the GMP lab, and Harley Street (CPC) is a clinical study into the pain relief benefits of medicinal cannabis.

Celadon Pharmaceuticals (LSE:CEL) Headlines

No Headlines